{"disease":{"id":"norovirus-infections","name":"norovirus infections"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT05916326","title":"Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8000,"lead_sponsor_name":"National Vaccine and Serum Institute, China","has_results":false},{"nct_id":"NCT04941261","title":"Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":1716,"lead_sponsor_name":"National Vaccine and Serum Institute, China","has_results":false},{"nct_id":"NCT04188691","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":510,"lead_sponsor_name":"National Vaccine and Serum Institute, China","has_results":false},{"nct_id":"NCT05212168","title":"Norovirus Challenge Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Vaxart","has_results":true},{"nct_id":"NCT05626803","title":"A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Vaxart","has_results":true},{"nct_id":"NCT07254728","title":"A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Vaxart","has_results":true},{"nct_id":"NCT04854746","title":"Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Vaxart","has_results":false},{"nct_id":"NCT06944717","title":"A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Vaxart","has_results":false},{"nct_id":"NCT04875676","title":"Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Vaxart","has_results":true},{"nct_id":"NCT05213728","title":"A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Vaxart","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}